THERAPY DOSSIER · th-aac7b9985fa4

Delta-tocotrienol (DT3), a natural vitamin E isoform

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: DT3; delta-T3
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04245865 ↗PHASE2active not recruiting

Tocotrienol and bevacizumab in metastatic colorectal cancer: randomized phase II marker trial

Colorectal Cancer Metastatic

Enrolment: 83 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24294967 ↗2013Reported benefit

Delta-tocotrienol protects mice from radiation-induced gastrointestinal injury.

MouseRadiationCD2F1malesubcutaneous75-100 mg/kg (75 mg/kg effective)24 h before total-body irradiation

Model: Acute radiation gastrointestinal syndrome after 10-12 Gy 60Co total-body irradiation at 0.6 Gy/min

Delta-tocotrienol at 75 mg/kg significantly enhanced survival across 10 to 12 Gy total-body irradiation, protected intestinal tissue and crypts, reduced apoptotic cells in the jejunum, inhibited gut bacterial translocation, and suppressed radiation-induced IL-1beta, IL-6 and PTK6 expression.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…